ENDOSCOPY
SOLUTIONS
ANESTHESIA &
PATIENT MONITORING
Ambu’s primary growth driver, Endoscopy Solutions,
accounted for 64% of the total revenue in Q3 2025/26
and delivered strong organic growth of 16.0% (15.9%).
Urology delivered solid performance in a fast-growing
market, driven by very strong volume growth and a rising
number of decision-makers recognizing single-use as
standard of care. Cystoscopy momentum was strong,
supported by Ambu’s market leadership, while
ureteroscopy continued to be impacted by long sales
cycles as hospitals evaluate a growing number of single-
use solutions. We are confident in our ability to continue
to gain share through high-quality clinical performance,
EndoIntelligence, and further innovation. ENT gained
further traction, driven by healthcare providers' efforts to
reduce waiting lists through more outpatient and ASC
procedures, supported by the cost advantages of our
solutions. GI continued to build momentum, driven by
increasing customer adoption and strong purchase rates.
Anesthesia & Patient Monitoring accounted for 36% of Ambu’s
total revenue in Q3 2025/26, with organic growth of 1.6%
(6.4%). While the business returned to positive growth, there
continues to be a headwind from the annualization effect of
the commercial changes that we outlined in the Q2 2025/26
interim report. This was partly offset by solid commercial
execution and a market-leading portfolio that is supported by
strong brand recognition among customers.
Performance was driven by solid execution and
momentum across all endoscopy areas, reflecting
demand for Ambu’s innovative solutions and reinforcing
our leadership in driving the conversion from reusable to
single-use solutions.
Drivers of the quarter
Drivers of the quarter
The global healthcare market for anesthesiology, neurology,
and cardiology remained stable and growing, driven by
increasing procedure volumes and supported by demographic
trends and expanding access to healthcare.
The global endoscopy market remained strong,
supported by increasing procedure volumes and growing
adoption of single-use solutions, with Ambu leading the
transition from reusable to single-use endoscopes.
Anesthesia posted -0.4% (3.9%) organic growth. As
mentioned previously, growth was impacted by price
increases implemented in prior years, which led to lower
volumes in Anesthesia in selected U.S. accounts operating
under non-exclusive contracts.
Continued investment in innovative solutions
In the third quarter, Ambu launched SureSight Mobile,
further strengthening our Respiratory full-solution
offering. We are seeing strong customer feedback,
highlighting the value of a solution that supports
clinicians across a wide range of procedures.
Respiratory delivered organic revenue growth of 17.1%
(11.2%), reflecting accelerated momentum. Growth was
driven by increasing demand for our bronchoscopy
portfolio, which continues to improve clinical
performance and workflow efficiency, further supporting
single-use adoption as the future standard of care. In
addition, SureSight is becoming an important growth
driver, both directly and by supporting broader adoption
of our bronchoscopy portfolio. This underpins our
confidence in a strong near- to mid-term growth
trajectory for Respiratory and demonstrates our ability to
leverage our leadership position through full-solution
selling, backed by EndoIntelligence.
Patient Monitoring posted 3.6% (9.3%) organic growth.
Growth was driven by our market-leading portfolio. Especially,
neurology delivered strong growth, supported by an attractive
and growing market driven by increasing treatment of
neurological conditions.
Our full-solution strategy is expected to support the
ongoing conversion from reusable to single-use
endoscopes while further strengthening Ambu’s
differentiated position as the only provider offering a
comprehensive single-use endoscopy portfolio.
We have expanded our neurology portfolio with FDA approval
and CE marking for Neuroline Cup MRI/CT-compatible EEG
electrodes. The solution will not have any impact for this
financial year, as commercialization begins at the start of next
year. The launch will support the 3-5% growth in Anesthesia &
Patient Monitoring throughout the strategy period.
We continue to advance our EndoIntelligence platform,
expanding our innovation model beyond hardware
through software and AI capabilities that enhance image
quality, cybersecurity, and connectivity to electronic
health records. This supports workflow optimization at
hospitals and strengthens the value proposition of our
comprehensive endoscopy portfolio.
‘Urology, ENT & GI’ posted organic revenue growth of
15.0% (20.8%), reflecting strong underlying demand for
single-use solutions. Growth was largely driven by
cystoscopy and rhinolaryngology, where Ambu’s
solutions support higher patient throughput and align
well with the ongoing migration of procedures to
outpatient / ambulatory surgery center (ASC) settings.
Q3 2025/26
Q3 2025/26
organic growth
16.0%
1.6%
organic growth
Company announcement no. 17 2025/26
|
25 August 2026
5
